Skip to content
Peptigraph home

Survodutide Phase 2 trial (NCT04771273)

Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
295
actual
Start
27 Apr 2021 (actual)
Primary completion
9 Nov 2023 (actual)
Sponsor
Boehringer Ingelheim
Design

Arms and doses

NCT04771273 study arms
ArmTypeInterventionsDescription
Survodutide 2.4 mg - planned maintenance treatmentExperimentalDrug: SurvodutideNot stated
Survodutide 4.8 mg - planned maintenance treatmentExperimentalDrug: SurvodutideNot stated
Survodutide 6.0 mg - planned maintenance treatmentExperimentalDrug: SurvodutideNot stated
Placebo - planned maintenance treatmentPlacebo comparatorDrug: PlaceboNot stated
Endpoints

Primary endpoint

NCT04771273 primary outcomes
MeasureTime frame
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance TreatmentAt baseline and at 48 weeks.
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance TreatmentAt baseline and after 48 weeks of treatment.
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04771273 secondary outcomes
MeasureTime frame
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance TreatmentAt baseline and after 48 weeks.
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance TreatmentAt baseline and at 48 weeks.
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance TreatmentMMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance TreatmentMMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance TreatmentMMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance TreatmentMMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance TreatmentAt baseline and after 48 weeks of treatment.
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance TreatmentAt baseline and after 48 weeks of treatment.
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance TreatmentAt baseline and 48 weeks of treatment.
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance TreatmentAt baseline and 48 weeks of treatment.
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04771273.

Survodutide in biopsy-confirmed MASH with fibrosis

Adults with biopsy-confirmed MASH and fibrosis stage F1 to F3 were randomised 1:1:1:1 to survodutide 2.4, 4.8 or 6.0 mg or placebo for 48 weeks.[2]

MASH improved without worsening of fibrosis in 47%, 62% and 43% of the three survodutide groups against 14% on placebo.[2]

Liver fat fell by at least 30% in 63%, 67% and 57% of survodutide participants and 14% on placebo; fibrosis improved by one stage in 34%, 36%, 34% and 22%.[2]

Nausea (66% vs. 23%), diarrhea (49% vs. 23%) and vomiting (41% vs. 4%) were more frequent with survodutide, with serious events at 8% against 7%.[2]

Sources

  1. 1Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026

Found an error? Report a correction.